The NKG2A immune checkpoint - a new direction in cancer immunotherapy

被引：73

作者：

Creelan, Benjamin C. ^{[1
]}

Antonia, Scott J. ^{[1
,2
]}

机构：

[1] H Lee Moffitt Canc Ctr & Res Inst, Thorac Oncol Dept, Tampa, FL 33612 USA

[2] Duke Canc Inst, DCI Ctr Canc Immunol, Durham, NC USA

来源：

NATURE REVIEWS CLINICAL ONCOLOGY | 2019年 / 16卷 / 05期

关键词：

D O I：

10.1038/s41571-019-0182-8

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Inhibition of the NKG2A immune checkpoint restores natural killer cell and T cell effector function in preclinical cancer models. In addition, NKG2A blockade in combination with other therapeutic antibodies is showing encouraging responses in a subset of patients with metastatic colorectal or head and neck cancer. However, established biomarkers of response are lacking, and larger trials are needed to enable firm conclusions to be drawn about whether NKG2A inhibition complements existing immunotherapies.

引用

下载

页码：277 / 278

页数：2

共 50 条

[21] Monalizumab Anti-NKG2A monoclonal antibody, Checkpoint inhibitor, Cancer immunotherapy
Gajdosik, Z.
DRUGS OF THE FUTURE, 2019, 44 (09) : 699 - 704
[22] Immune checkpoint signaling and cancer immunotherapy
Xing He
Chenqi Xu
Cell Research, 2020, 30 : 660 - 669
[23] Immune checkpoint inhibitors in cancer immunotherapy
Himmel, Megan E.
Saibil, Samuel D.
Saltman, Alexandra P.
CANADIAN MEDICAL ASSOCIATION JOURNAL, 2020, 192 (24) : E651 - E651
[24] Immune checkpoint signaling and cancer immunotherapy
He, Xing
Xu, Chenqi
CELL RESEARCH, 2020, 30 (08) : 660 - 669
[25] Setting traps for NKG2A gives NK cell immunotherapy a fighting chance
Cichocki, Frank
Miller, Jeffrey S.
JOURNAL OF CLINICAL INVESTIGATION, 2019, 129 (05): : 1839 - 1841
[26] Is CD94/NKG2A a novel target for lymphoid malignancies immunotherapy?
Urbaniak-Kujda, Donata
Dybko, Jaroslaw
Prajs, Iwona
Kielbinski, Marek
Tomaszewska-Toporska, Beata
Kapelko-Slowik, Katarzyna
Kuliczkowski, Kazimierz
BLOOD, 2006, 108 (11) : 243B - 243B
[27] The NK cell checkpoint NKG2A maintains expansion capacity of human NK cells
Kaulfuss, Meike
Mietz, Juliane
Fabri, Astrid
vom Berg, Johannes
Munz, Christian
Chijioke, Obinna
SCIENTIFIC REPORTS, 2023, 13 (01)
[28] The NK cell checkpoint NKG2A maintains expansion capacity of human NK cells
Meike Kaulfuss
Juliane Mietz
Astrid Fabri
Johannes vom Berg
Christian Münz
Obinna Chijioke
Scientific Reports, 13
[29] Beyond immune checkpoint: First-in-class antibody targeting soluble NKG2D ligand sMIC for cancer immunotherapy
Wu, Jennifer D.
Zhang, Jinyu D.
Basher, Fahmin
Rubinstein, Mark
CANCER IMMUNOLOGY RESEARCH, 2017, 5 (03)
[30] The inhibitory receptor NKG2A acts as a checkpoint on CD8 T cells in the context of cancer vaccines.
van Hall, Thorbald
van Montfoort, Nadine
Borst, Linda
Korrer, Michael J.
Kim, Young
Andre, Pascale
Wagtmann, Nicolai
Piersma, Sytse
van der Burg, Sjoerd H.
CANCER IMMUNOLOGY RESEARCH, 2020, 8 (04) : 81 - 81

← 1 2 3 4 5 →